Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.
Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronic kidney disease.
复制标题
一名患有类风湿性关节炎和慢性肾病的老年女性因狄诺塞麦导致严重低钙血症和 QT 间期延长。
DOI：
10.5152/eurjrheum.2015.0049
复制
发表时间：
2016
影响因子：
1.9
通讯作者：
S. Mokuda
中科院分区：
文献类型：
--
作者：
H. Oiwa;S. Mokuda
Denosumab已被批准用于预防骨转移相关事件（每4周120毫克）和治疗骨质疏松症（每6个月60毫克）。denosumab后低钙血症发生在5.2%的癌症患者中(1)，但在骨质疏松症患者中很少报道(2)。最近，在慢性肾脏疾病（CKD）患者中，由于低剂量的denosumab治疗骨质疏松导致严重的低钙血症（3,4）。我们描述了第一例类风湿关节炎（RA）和CKD与严重低钙血症和延长QT间期后给予低剂量的地诺单抗。
Denosumab has been approved for the prevention of skeletal-related events of bone metastases (120 mg at every 4 weeks) and for the treatment of osteoporosis (60 mg at every 6 months). Post-denosumab hypocalcemia occurred in 5.2% of the cancer patients (1), but such an event was rarely reported in osteoporosis patients (2). Recently, severe hypocalcemia because of a lower dose of denosumab for osteoporosis has been reported in chronic kidney disease (CKD) patients (3, 4). We describe the first case of rheumatoid arthritis (RA) and CKD associated with severe hypocalcemia and prolonged QT interval after the administration of a lower dose of denosumab.